Cardiovascular Diseases
The Gesundheitscentrum Mainz is conducting research on heart failure subtypes, specifically HFpEF and HFmrEF, exploring how inflammation and obesity influence outcomes.
- Evaluation of anti‑inflammatory therapy in HFpEF/HFmrEF patients
- Impact of obesity on heart failure progression
- Assessment of cardiovascular death and hospitalization risk
- Integration of novel agents such as ziltivekimab and NNC0487-0111
Ongoing studies aim to improve treatment effectiveness by testing new drugs that may reduce cardiovascular events and enhance quality of life for individuals living with these conditions.
